The Human Microbiome in Immune-Mediated Diseases
NCT02394964 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 75
Last updated 2023-12-21
Summary
The immune system is influenced by the commensal microbes that live in the gut and on the skin. This study aims to characterize the microbiota of subjects with autoimmune disease in order to determine whether certain microbial species may cause or worsen immune-mediated diseases
Conditions
Interventions
- OTHER
-
Sample Collection
Sample collection of blood, stool, and buccal and skin swab samples will be collected at baseline, week 4, and week 8
Sponsors & Collaborators
-
National Institutes of Health (NIH)
collaborator NIH -
Arthritis Foundation
collaborator OTHER -
National Institute of Allergy and Infectious Diseases (NIAID)
collaborator NIH -
Yale University
lead OTHER
Principal Investigators
-
Martin Kriegel, MD, PhD · Yale University
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2014-11-30
- Primary Completion
- 2023-12-31
- Completion
- 2023-12-31
Countries
- United States
Study Locations
More Related Trials
-
COVID-19 Vaccine Responses in PIDD Subjects
NCT05321407 ·Status: ACTIVE_NOT_RECRUITING
-
Study of the Frequency and of the Regulatory Function of Positive T Lymphocytes Dual CD4CD8aa (DP8a) Specific to a Bacteria of the Intestinal Microbiota (Faecalibacterium Prausnitzii) in Atopic Dermatitis, Asthma and Allergic Rhinitis
NCT02908360 ·Status: COMPLETED
-
STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable Immunodeficiency
NCT00263237 ·Status: COMPLETED ·Phase: PHASE1
-
Healthy-donor Microbiome MTP-101-C in Steroid Relapse/Refractory Immune-related Cutaneous Adverse Events (irCAEs) and Immune-mediated Colitis (IMC)
NCT06499896 ·Status: RECRUITING ·Phase: PHASE2
-
Interleukin-1 Trap to Treat Autoinflammatory Diseases
NCT00094900 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases
NCT02990286 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases
NCT02780674 ·Status: COMPLETED ·Phase: PHASE1
-
Biomarkers in Participants With Hidradenitis Suppurativa Receiving Guselkumab.
NCT04084665 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis
NCT00001761 ·Status: COMPLETED ·Phase: PHASE1
-
Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995
NCT02082353 ·Status: UNKNOWN
-
Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib
NCT03591770 ·Status: TERMINATED ·Phase: PHASE4
-
Safety and Efficacy of Abatacept in IgG4-Related Disease
NCT03669861 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab for Anti-cytokine Autoantibody-Associated Diseases
NCT01842386 ·Status: COMPLETED ·Phase: PHASE1
-
Bronchial Inflammation in Patients With Severe Immune Deficiency Under Immunoglobulin Treatment
NCT01359384 ·Status: UNKNOWN
-
Efficacy of Interleukin-2 Gargle in the Treatment of Oral Mucosa Lesion in Pemphigus Vulgaris
NCT04023149 ·Status: UNKNOWN ·Phase: PHASE2
-
A Long-term Extension Study of Ustekinumab in Pediatric Participants
NCT05092269 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Epigenetic Regulation of Altered T-cell Immunity in Sarcoidosis
NCT03145922 ·Status: RECRUITING
-
Use of Erythropoietin to Expand Regulatory T Cells in Autoimmune Liver Disease
NCT03842254 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Aimmune Longitudinal Collaboration Study
NCT07218640 ·Status: RECRUITING ·Phase: NA
-
A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).
NCT04425538 ·Status: COMPLETED ·Phase: PHASE2
-
An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study
NCT05192200 ·Status: COMPLETED ·Phase: PHASE2
-
A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease
NCT01211977 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications
NCT05104723 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Comparative Analysis of the Th17 Cellular Response in Active and Inactive Pemphigus Vulgaris Patients
NCT04096222 ·Status: UNKNOWN
-
An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies
NCT00072592 ·Status: COMPLETED ·Phase: PHASE1